Evotec SE

1EVT

Company Profile

  • Business description

    Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

  • Contact

    Essener Bogen 7
    Manfred Eigen Campus
    Hamburg22419
    DEU

    T: +49 40560810

    E: [email protected]

    https://www.evotec.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2025

    Employees

    4,766

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,785.6043.10-0.49%
CAC 407,766.7143.240.56%
DAX 4024,206.91133.240.55%
Dow JONES (US)44,240.76165.60-0.37%
FTSE 1008,854.1847.650.54%
HKSE23,965.79182.28-0.75%
NASDAQ20,418.465.950.03%
Nikkei 22539,791.74102.930.26%
NZX 50 Index12,768.6190.41-0.70%
S&P 5006,225.524.46-0.07%
S&P/ASX 2008,547.3043.40-0.51%
SSE Composite Index3,511.8314.360.41%

Market Movers